Site-073 — Midlothian, Virginia

Site-073 is a clinical research site located in Midlothian, Virginia, United States 23112.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Site-073 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Graves Disease.

Sponsors: Biohaven Therapeutics Ltd..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Midlothian

Browse all research sites in Virginia · View every site in Midlothian

• Cardiovascular Associates of Virginia-Bon Secours St. Mary's Hospital
• Bon Secours St. Mary's Hospital
• Bon Secours St Francis Hospital
• Bon Secours St Marys Hospital Richmond
• Bon Secours Richmond Community Hospital dba Oncology Associates at St. Francis Medical Center
• Bon Secours Saint Francis Medical Center
• Bon Secours Westchester Emergency Center
• Research Site
• Virginia Research Center
• Dominion Clinical Research
• Bon Secours St Francis Medical Center
• GSK Investigational Site

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site-073?

Site-073 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site-073 conducted?

Site-073 has 1 clinical trials on record, with 1 currently active. Their work covers Graves Disease.

Is Site-073 accredited by Crixeo Clinical Trials?

Site-073 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site-073?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.